ICOSLG and mesothelioma: In such a context, we designed the AdV5/3-D24-ICOSL-CD40L (25) oncolytic vector and tested its anti-cancer effectiveness along with an anti-PD-1 antibody in both immunodeficient and humanized xenografted mesothelioma H226 mouse model.